<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>American Diabetes Association</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>MWN-105 ameliorates MASH symptoms in the preclinical setting</title>
      <description>
        <![CDATA[Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that has limited available therapies. Shanghai Minwei Biotechnology Co. Ltd. has developed and presented data for MWN-105, a GLP-1/GIP/FGF21 triple agonist aimed at controlling metabolic dysfunction and fibrosis during MASH.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721996</guid>
      <pubDate>Wed, 09 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721996-mwn-105-ameliorates-mash-symptoms-in-the-preclinical-setting</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.webp?t=1709588066" type="image/jpeg" medium="image" fileSize="175206">
        <media:title type="plain">Liver over digital lens background</media:title>
      </media:content>
    </item>
    <item>
      <title>Insparin, a promising antidiabetic peptide</title>
      <description>
        <![CDATA[Insparin is a protein isolated from human adenovirus Ad36 that induces cellular glucose uptake without impacting safety. A preclinical study of insparin looked at its potential antidiabetic effects compared to those of pioglitazone.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721758</guid>
      <pubDate>Fri, 04 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721758-insparin-a-promising-antidiabetic-peptide</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Peptide-illustration.webp?t=1600461887" type="image/png" medium="image" fileSize="74496">
        <media:title type="plain">Peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Eccogene’s ECC-4703 leads to greater weight loss in preclinical studies </title>
      <description>
        <![CDATA[Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an agonist of thyroid hormone receptor β (THR-β) and its metabolic impact on preclinical models of obesity in combination with semaglutide was investigated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721743</guid>
      <pubDate>Thu, 03 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721743-eccogenes-ecc-4703-leads-to-greater-weight-loss-in-preclinical-studies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Pills-bottle-scale-and-measuring-tape.webp?t=1704492123" type="image/jpeg" medium="image" fileSize="266968">
        <media:title type="plain">Pills, bottle, scale and-measuring tape</media:title>
      </media:content>
    </item>
    <item>
      <title>ASC-47 shows superior weight loss effect compared to semaglutide</title>
      <description>
        <![CDATA[ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in healthy subjects and in patients with obesity, respectively.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721725</guid>
      <pubDate>Wed, 02 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721725-asc-47-shows-superior-weight-loss-effect-compared-to-semaglutide</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/stomach-weight-loss-caliper-body-fat.webp?t=1736785357" type="image/jpeg" medium="image" fileSize="185267">
        <media:title type="plain">Woman measuring her body fat with caliper</media:title>
      </media:content>
    </item>
    <item>
      <title>BI-4659 reverses diet-induced obesity in mice</title>
      <description>
        <![CDATA[Therapies based on glucagon-like peptide 1 (GLP-1) are the most effective for treating obesity to date, but their efficacy and tolerability are limited by gastrointestinal side effects and compensatory reduction of energy expenditure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721662</guid>
      <pubDate>Tue, 01 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721662-bi-4659-reverses-diet-induced-obesity-in-mice</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Man-measuring-waist.webp?t=1696021724" type="image/jpeg" medium="image" fileSize="195747">
        <media:title type="plain">Man measuring waist</media:title>
      </media:content>
    </item>
    <item>
      <title>TLC-1180 supports durable weight loss and metabolic gains in combination approaches</title>
      <description>
        <![CDATA[Synthetic mitochondrial protonophores uncouple ATP production, increasing tricarboxylic acid (TCA) cycle activity and fat oxidation to meet energy demands. This approach promotes weight loss and may also enhance glycemic control and lipid metabolism.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721660</guid>
      <pubDate>Tue, 01 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721660-tlc-1180-supports-durable-weight-loss-and-metabolic-gains-in-combination-approaches</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Obesity-adipose-tissue-fat-cells.webp?t=1663945779" type="image/png" medium="image" fileSize="1468259">
        <media:title type="plain">Light micrograph and 3D illustration of adipose tissue. </media:title>
      </media:content>
    </item>
    <item>
      <title>Preclinical characterization of antiobesity drug MET-097</title>
      <description>
        <![CDATA[MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials. &nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/721595</guid>
      <pubDate>Mon, 30 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721595-preclinical-characterization-of-antiobesity-drug-met-097</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/obesity-doctor-patient-weight.webp?t=1589291209" type="image/png" medium="image" fileSize="427781">
        <media:title type="plain">Doctor measuring patient's waist</media:title>
      </media:content>
    </item>
    <item>
      <title>OB-756 shows therapeutic efficacy in type 1 diabetes</title>
      <description>
        <![CDATA[The main feature of type 1 diabetes is the destruction of pancreatic β cells that produce insulin. Immunotherapy directed at inhibiting immune interactions between cytokines and islet cells and preserving its functioning is key to reverse the progression of the disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721578</guid>
      <pubDate>Fri, 27 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721578-ob-756-shows-therapeutic-efficacy-in-type-1-diabetes</link>
    </item>
    <item>
      <title>IBI-3030 protects against cardiovascular risk in mice</title>
      <description>
        <![CDATA[IBI-3030 from Innovent Biologics Inc. is a novel antibody-peptide conjugate targeting PCSK9 that shows agonism for GLP-1R, GCGR and GIPR, aimed to confer therapeutic benefit against cardiovascular disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721577</guid>
      <pubDate>Fri, 27 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721577-ibi-3030-protects-against-cardiovascular-risk-in-mice</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-with-blocked-arteries.webp?t=1678140599" type="image/png" medium="image" fileSize="369283">
        <media:title type="plain">Heart with blocked arteries</media:title>
      </media:content>
    </item>
    <item>
      <title>ACCG-2671 reduces body weight in DIO rats</title>
      <description>
        <![CDATA[Amylin is an attractive target in the management of obesity, since it is a peptide hormone co-secreted with insulin in response to food intake, and suppresses appetite and delays gastric emptying. At the American Diabetes Association's Scientific Sessions in Chicago, Structure Therapeutics Inc. presented data regarding the dual amylin receptor and calcitonin receptor agonist ACCG-2671 for obesity treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721545</guid>
      <pubDate>Thu, 26 Jun 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721545-accg-2671-reduces-body-weight-in-dio-rats</link>
    </item>
    <item>
      <title>Multiple multianalyte sensors for diabetes on horizon</title>
      <description>
        <![CDATA[Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ketones as well as glucose.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721229</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721229-multiple-multianalyte-sensors-for-diabetes-on-horizon</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-21-Abbott-sign.webp?t=1603296108" type="image/png" medium="image" fileSize="579854">
        <media:title type="plain">Abbott sign</media:title>
        <media:description type="plain">Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>In-patient BYOD still troublesome for CGM makers</title>
      <description>
        <![CDATA[With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, bringing your own device or using personal CGMs to measure glucose levels during hospitalizations seems like a no-brainer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721227</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721227-in-patient-byod-still-troublesome-for-cgm-makers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Dexcom-G6-11-11.webp?t=1600984902" type="image/png" medium="image" fileSize="640671">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">G6 CGM system. Credit: Dexcom Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Two new options presented at ADA for early diagnosis of T1D</title>
      <description>
        <![CDATA[Classically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels. At the 85th Scientific Sessions of the American Diabetes Association in Chicago, researchers highlighted two options – a blood test and a machine learning model – for diagnosing the disease much earlier in its progression, when damage to the pancreas' beta cells could be slowed. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721219</guid>
      <pubDate>Tue, 24 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721219-two-new-options-presented-at-ada-for-early-diagnosis-of-t1d</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/Diabetes-illustration.webp?t=1724186440" type="image/png" medium="image" fileSize="300125">
        <media:title type="plain">Blood glucose chart and monitor, stethoscope, injector pen</media:title>
      </media:content>
    </item>
    <item>
      <title>Fractyl pursues dual track to cure T2 diabetes</title>
      <description>
        <![CDATA[At the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results from two studies evaluating very different approaches to treating – and possibly curing – type 2 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721208</guid>
      <pubDate>Mon, 23 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721208-fractyl-pursues-dual-track-to-cure-t2-diabetes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-30-fractyl-revita.webp?t=1723150591" type="image/png" medium="image" fileSize="571869">
        <media:title type="plain">Illustration of Revita DMR in intestine</media:title>
        <media:description type="plain">Revita duodenal mucosal resurfacing system. Credit: Fractyl Laboratories Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Liver-targeted siRNA improves body composition in mouse models</title>
      <description>
        <![CDATA[Large-scale human genetic studies have revealed that loss-of-function INHBE variants are associated with a lower abdominal to gluteofemoral fat ratio, improved metabolic profile, and reduced fasting glucose levels.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710165</guid>
      <pubDate>Mon, 08 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710165-liver-targeted-sirna-improves-body-composition-in-mouse-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration-purple.webp?t=1705415419" type="image/jpeg" medium="image" fileSize="218236">
        <media:title type="plain">Liver illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>METTL2A as a therapeutic target in obesity and metabolic disorders</title>
      <description>
        <![CDATA[After finding a mutation in METTL2A in a family with diabetes exhibiting a special phenotype, investigators at Zhejiang University School of Medicine studied its role in glucose and lipid metabolism in METTL2 (murine orthologue) knockout mice and wild-type mice fed a normal chow or a high-fat diet (HFD) for 20 weeks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710088</guid>
      <pubDate>Wed, 03 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710088-mettl2a-as-a-therapeutic-target-in-obesity-and-metabolic-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Metabolism-obesity-fat-cell-research.webp?t=1664551531" type="image/png" medium="image" fileSize="1520755">
        <media:title type="plain">Obesity, fat cell research concept image</media:title>
      </media:content>
    </item>
    <item>
      <title>Galectin-3 inhibitor confers protection against MASLD</title>
      <description>
        <![CDATA[Metabolic dysfunction-associated steatotic liver disease (MASLD) has a prevalence of about 25% in the adult population, with steatosis present in >5% of hepatocytes, hepatocyte ballooning and fibrosis as the main hallmarks. Scientists have tested effects of the galectin-3 inhibitor modified citrus pectin (MCP) in <em>ApoE</em> knockout mice fed a western diet.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710055</guid>
      <pubDate>Tue, 02 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710055-galectin-3-inhibitor-confers-protection-against-masld</link>
    </item>
    <item>
      <title>Shionogi’s MGAT2 inhibitor improves metabolism in obesity models </title>
      <description>
        <![CDATA[Targeting monoacylglycerol <em>O</em>-acyltransferase 2 (MGAT2), an enzyme highly expressed in the small intestine, has been validated as an antiobesity strategy in the preclinical setting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710046</guid>
      <pubDate>Tue, 02 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710046-shionogis-mgat2-inhibitor-improves-metabolism-in-obesity-models</link>
    </item>
    <item>
      <title>Biolexis Therapeutics’ AMPK activator shows preclinical efficacy in obesity, type 2 diabetes </title>
      <description>
        <![CDATA[Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake in human tissue.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710033</guid>
      <pubDate>Mon, 01 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710033-biolexis-therapeutics-ampk-activator-shows-preclinical-efficacy-in-obesity-type-2-diabetes</link>
    </item>
    <item>
      <title>MTX-101 restores CD8 Treg functioning and provides resistance to autoimmunity progression</title>
      <description>
        <![CDATA[MTX-101 (Mozart Therapeutics Inc.) is a bispecific CD8 Treg modulator that targets CD8 and the KIR2DL family, including KIR2DL1, KIR2DL2 and KIR2DL3, and is being developed for the treatment of CD4-driven autoimmunity and restoring immune balance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710029</guid>
      <pubDate>Mon, 01 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710029-mtx-101-restores-cd8-treg-functioning-and-provides-resistance-to-autoimmunity-progression</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Treg-cells.webp?t=1578609989" type="image/png" medium="image" fileSize="247982">
        <media:title type="plain">Treg cells</media:title>
      </media:content>
    </item>
    <item>
      <title>NA-931 reduces body weight and improves metabolic profile in obese mice</title>
      <description>
        <![CDATA[Biomed Industries Inc. has presented data on its IGF-1/GLP-1/GIP/GCGR quadruple agonist NA-931 for the treatment of obesity and metabolic disorders. The company has discovered a family of IGF-1 metabolites, known as NA-931, and its analogues NA-932 and NA-933, which are referred to as NA-931 compounds.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710027</guid>
      <pubDate>Mon, 01 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710027-na-931-reduces-body-weight-and-improves-metabolic-profile-in-obese-mice</link>
    </item>
    <item>
      <title>GLP-1R agonist CT-996 reduces body weight and fat mass in obese animals</title>
      <description>
        <![CDATA[Injectable glucagon-like peptide 1 receptor (GLP-1R) agonists have shown efficacy in weight management and glycemic control. Semaglutide is available as an oral formulation, but it requires specific timing and conditions. Carmot Therapeutics Inc. has presented data for its oral GLP-1R agonist CT-996 from preclinical studies in obesity; the drug is currently in early clinical development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710009</guid>
      <pubDate>Fri, 28 Jun 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710009-glp-1r-agonist-ct-996-reduces-body-weight-and-fat-mass-in-obese-animals</link>
    </item>
    <item>
      <title>No longer a two-horse race: Obesity drug competition expands</title>
      <description>
        <![CDATA[The obesity market is hot with Novo Nordisk A/S generating $6.3 billion in sales from its semaglutide-containing drugs, Ozempic, Saxenda, Rybelsus and Wegovy, in the first quarter of 2024 and Eli Lilly and Co. bringing in $2.3 billion for its tirzepatide-containing drugs, Zepbound and Mounjaro, in the same quarter. It appears unlikely the market will be a two-horse race for much longer though.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710103</guid>
      <pubDate>Thu, 27 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710103-no-longer-a-two-horse-race-obesity-drug-competition-expands</link>
      <media:content url="https://www.bioworld.com/ext/resources/2024/06/27/Blue-injector-pens.webp?t=1719525960" type="image/jpeg" medium="image" fileSize="231384">
        <media:title type="plain">Blue injector pens</media:title>
      </media:content>
    </item>
    <item>
      <title>More support for glucose monitors in type 2 diabetes</title>
      <description>
        <![CDATA[Continuous glucose monitors continue to post positive results for managing diabetes in an ever-expanding population. Long a mainstay of disease management for those with type 1 diabetes, the devices have also proved themselves in treating type 2 diabetes that requires multiple daily injections of insulin.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709633</guid>
      <pubDate>Wed, 26 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709633-more-support-for-glucose-monitors-in-type-2-diabetes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tandem pumps up interest in Mobi insulin delivery system</title>
      <description>
        <![CDATA[All eyes were on Tandem Diabetes Care Inc.’s presentation of the tiny Mobi pump at a standing-room-only event during the American Diabetes Association’s 84th Scientific Sessions in Orlando. In addition to showcasing the 18 ways the device can be worn, Tandem highlighted results from its user survey which found that 86% of respondents reported that the device improved their quality of life.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709615</guid>
      <pubDate>Tue, 25 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709615-tandem-pumps-up-interest-in-mobi-insulin-delivery-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/07-11-tandem-mobi.webp?t=1689114491" type="image/jpeg" medium="image" fileSize="543026">
        <media:title type="plain">Tandem Mobi in pocket</media:title>
        <media:description type="plain">Tandem’s FDA-cleared Mobi pump is small enough to fit in a coin pocket.</media:description>
      </media:content>
    </item>
    <item>
      <title>Endogenex raises $88M for Recet trial in T2D</title>
      <description>
        <![CDATA[Endogenex Inc. closed an oversubscribed $88 million series C financing round to support completion of its investigational device exemption trial for the Recet system. The Recet system uses non-thermal pulsed electric fields to remodel the duodenal tissue to treat adults with type 2 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709614</guid>
      <pubDate>Tue, 25 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709614-endogenex-raises-88m-for-recet-trial-in-t2d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Endogenex-Recet-5-31.webp?t=1685569753" type="image/jpeg" medium="image" fileSize="123505">
        <media:title type="plain">Endogenex-Recet-5-31.jpg</media:title>
        <media:description type="plain">Endogenex Inc.’s ReCET procedure uses pulsed electrical field ablation to remodel the lining of the duodenum and increase insulin sensitivity in people with type 2 diabetes, allowing most to discontinue insulin.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADA offers better reading on Medtronic’s future in diabetes</title>
      <description>
        <![CDATA[Medtronic plc’s diabetes unit has not received the positive attention lavished on competitors in recent years, but that may be about to change, if its presentations and analysts’ views from the American Diabetes Association 84th Scientific Sessions this weekend provide a good measure. Perhaps most notably, Medtronic’s Mimimed 780G, a hybrid closed-loop automated insulin delivery system that received U.S. FDA clearance in April 2023, posted strong results and could be the catalyst for increased traction of the diabetes franchise.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709611</guid>
      <pubDate>Mon, 24 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709611-ada-offers-better-reading-on-medtronics-future-in-diabetes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/medtronic-minimed-780G-24june24.webp?t=1719268014" type="image/jpeg" medium="image" fileSize="145133">
        <media:title type="plain">medtronic minimed 780G</media:title>
        <media:description type="plain">Medtronic minimed 780G</media:description>
      </media:content>
    </item>
    <item>
      <title>Insulet builds type 2 diabetes case</title>
      <description>
        <![CDATA[Results presented at the American Diabetes Association’s 84th Scientific Sessions in Orlando this weekend demonstrated significant reductions in blood glucose and insulin requirements in people with type 2 diabetes using Insulet Corp.’s Omnipod 5 automated insulin delivery (AID) system, providing a solid base for the company’s expansion into a much larger market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709610</guid>
      <pubDate>Mon, 24 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709610-insulet-builds-type-2-diabetes-case</link>
      <media:content url="https://www.bioworld.com/ext/resources/2023/05/08/OP5_INSU_POD_PDM_NoADH_RIGHT_RGB_With_Disclaimer.webp?t=1724789780" type="image/jpeg" medium="image" fileSize="69380">
        <media:title type="plain">OP5_INSU_POD_PDM_NoADH_RIGHT_RGB.jpg</media:title>
        <media:description type="plain">The Insulet Omnipod 5 AID.</media:description>
      </media:content>
    </item>
    <item>
      <title>Dexcom, Insulet expand device access ahead of ADA meeting</title>
      <description>
        <![CDATA[Dexcom Inc. and Insulet Corp. both reported introductions of their products into new countries on the eve of the 2024 American Diabetes Association annual meeting in Orlando, Fla. The two firms also announced the U.S. launch of Insulet’s Omnipod 5 tubeless automated insulin delivery system with connectivity to Dexcom’s G7, the company’s latest generation continuous glucose monitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709486</guid>
      <pubDate>Thu, 20 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709486-dexcom-insulet-expand-device-access-ahead-of-ada-meeting</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/insulet-dexcom-20june24.webp?t=1750973216" type="image/jpeg" medium="image" fileSize="93363">
        <media:title type="plain">insulet dexcom CGM</media:title>
        <media:description type="plain">Insulet’s Omnipod 5 with Dexcom G6 connectivity. Credit: Insulet Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADA meeting highlights new technologies for diabetes and updates for existing tech </title>
      <description>
        <![CDATA[Two companies presented highlights of studies that demonstrated outstanding results for novel devices at last weekend’s American Diabetes Association’s (ADA) 83rd Scientific Sessions, while Embecta Corp. and Senseonics Holdings Inc. provided updates that position them well for long-term performance. Glyconics Ltd. revealed a fingernail scanning device that simplifies screening for diabetes and Fractyl Health Inc. showed that its Revita procedure reduced blood glucose levels and promoted weight loss.]]>
      </description>
      <guid>http://www.bioworld.com/articles/698446</guid>
      <pubDate>Thu, 29 Jun 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/698446-ada-meeting-highlights-new-technologies-for-diabetes-and-updates-for-existing-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Clinical-research-concept-with-medical-icons-on-light-bulb.webp?t=1637005884" type="image/png" medium="image" fileSize="568501">
        <media:title type="plain">Clinical research concept with medical icons on light bulb</media:title>
      </media:content>
    </item>
  </channel>
</rss>
